Octofeb Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 09-01-2025
- Paid Up Capital ₹ 0.10 M
as on 09-01-2025
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.92 M
as on 09-01-2025
- Revenue 38.47%
(FY 2022)
- Profit -50.17%
(FY 2022)
- Ebitda 52.02%
(FY 2022)
- Net Worth -40.43%
(FY 2022)
- Total Assets -7.48%
(FY 2022)
About Octofeb Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.92 M.
Anshul Kumar and Gaurav Dawar serve as directors at the Company.
- CIN/LLPIN
U24304HR2017PTC068918
- Company No.
068918
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Karnal, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Octofeb Pharma Private Limited offer?
Octofeb Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Herbal Cough Syrup, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Juices, Soups & Soft Drinks, Instant Drink Mix, Respiratory System Drugs, Anti Asthma Drug, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Octofeb Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anshul Kumar  | Director | 04-May-2017 | Current |
| Gaurav Dawar | Director | 04-May-2017 | Current |
Financial Performance of Octofeb Pharma.
Octofeb Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 38.47% increase. The company also saw a substantial fall in profitability, with a 50.17% decrease in profit. The company's net worth observed a substantial decline by a decrease of 40.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Octofeb Pharma?
In 2020, Octofeb Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 18 Nov 2021 | ₹0.43 M | Open |
Canara Bank Creation Date: 17 Dec 2019 | ₹3.50 M | Open |
How Many Employees Work at Octofeb Pharma?
Unlock and access historical data on people associated with Octofeb Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Octofeb Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Octofeb Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
